Geleen, Netherlands
Geleen, Netherlands

DSM is a Dutch-based multinational life science and materials science company. DSM's global end markets include food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM has annual net sales of around €10 billion and employs some 24,500 people worldwide. The company is headquartered in the Netherlands, with locations on five continents. The company is listed on NYSE Euronext. Wikipedia.


Time filter

Source Type

News Article | May 24, 2017
Site: www.altenergystocks.com

In California, Amyris (AMRS) reported Q1 revenues of $13.0M compared with $8.8M for Q1 2016, and touted the “significant increase in product sales, primarily in the personal care and health and nutrition markets, offset by a slight decline in collaboration revenue.” Collaboration revenues contributed $4.7M and product sales added $8.3M for the quarter. As Jeff Osborne at Cowen & Co noted, “Amyris reported revenue of $13.0mn, well below our estimate of $37.1mn due to much lower collaboration payments than we had anticipated. Management has highlighted that these payments can be very lumpy in nature, and attributed the miss to a failed milestone payment from Ginkgo Bioworks. Gross Margin of 2% was well below our estimate of 40% due to the lower collaboration payments.” We liked one item more than anything. In Q1 2016, product sales were $5.2M and the cost of product sales were $11.2M, and a number of informed observers became alarmed that the company was losing money on every product produced, and that growth would be unsustainable. The company noted the concerns but said that future sales would arrive with stronger gross margins. So, let’s look at Q1 2017. And indeed, the company has staged a turnaround in that critical metric. In Q1 2017, product sales were $13.2M and the cost of product sales were $12.8M. IIt’s a rretunr to the kind of gross margins that company had achieved by Q3 2016 — but with a 50% jump in revenues. Long ways to go before the company is out the financial woods, but we may see here a turning point. The company recorded record quarterly Biossance sales following successful launch into Sephora with the brand delivering high growth and expected to drive much better than expected 2017 results — growing from approximately $500,000 in 2016 total retail sales to over $10 million expected for 2017 There wasn’t much insight offered regarding the Ginkgo situaiton, excepting that a mysterious milestone payment was missed — apparently, a huge one, because the miss on revenues compared to analyst expectations was almost $24M. Indeed, the scale-up news from the Ginkgo universe this past week went in a completely different direction. Ginkgo Bioworks and Robertet USA completed the commercial-scale fermentation of “a key flavor and fragrance ingredient” – which one, we don’t yet know. The specific scale was 50,000 liters. But think along the lines of rose oil ingredients and lactone ingredients — that’s the Robertet sector. Overall, Ginkgo has a portfolio of over 40 products under contract with 20 customers. The company highlighted three major developments that will positvely impact the company this year and next: “We are pleased with our continued execution delivering increased product sales and very healthy revenue growth for Amyris,” said John Melo, Amyris President & CEO. “We are very excited to join with Royal DSM to accelerate product sales in health and nutrition markets, deliver better performing products and accelerate market access. With their support and that of our investors we have significantly strengthened our balance sheet and the company’s foundation as a leading company in its sector.” Continued Melo, “Our product portfolio is growing at a faster rate than we expected within nutraceuticals, skin care and fragrance ingredients. We have evolved our business to predictable quarter on quarter product sales and continue to deliver on our strategic milestones for delivery of our collaboration revenue. While our competitors struggle to deliver material revenue and predictable growth we expect to deliver around $60 million of product revenue for 2017, or more than double from 2016, and we expect total revenue to be better than our 2017 plan. It’s the 5th consecutive quater of year on year product revemue growth, and the company is targeting $115-120M in revenue in 2017 and of that $60M is expected to come from product sales. In 2018, guidance is at $160M for product sales. All that’s the good news. Here’s the bad news, Amyris has been pushing back it’s time to $100M in revenue for some time. Back in May 2016 we heard from AMyris that it was “On track to execute 2016 business plan with expected non-GAAP revenue of $90-$105 million for the year.” The company ended up with $67M for the year — and with a $13M result in Q1, the company will need to average out at $33M per quarter to reach its $115M target in 2017. Needless to say, the next 90 days are perhaps the most important in the company’s lifespan. There’s a time for building the long-term future and there’s a time for delivering on stated goals. Wall Street may well be able to put the past in the past with all forgive if Amyris can break out and hit that $100M revenue threshold, and even with a strong second half, the company will need to reach something like $30M in Q2 revenue to maintain belief, given the 2016 miss.


Opportunities in Polymer and Plastic 3D Printing - 2017 is the third generation of the world's most comprehensive analysis of polymer 3D printing technology. In this new edition, market analysis is segmented by print technology market as each major polymer print process settles into its own roles and established applications, our analysis has deepened to the specifics of each driving print technology and associated materials. Over the last two years, the polymer 3D printing industry has been in a state of tumultuousness marked by dozens of new competitors entering the market, partnerships for development of materials, and development of new print technologies. All of these and more have combined to create a whirlwind market that, in spite of so much activity and investment, has struggled to maintain its growth pace from 2012 through 2014 as customers have backed off purchasing in the traditional segments while adopting a 'wait and see' strategy. The demand for additive manufacturing in general has perhaps never been higher, but challenges associated with such rapid evolution in polymer and plastic 3D printing have suppressed growth in the face of historic interest in 3D printing at a professional level. As the global chemical and polymer suppliers of the manufacturing world move into position to exert more influence over the increasingly integrated 3D printing industry, market change appears imminent. Meanwhile, the commercialization of disruptive new print technologies such as those from Carbon, HP, Rize, and more all ensure 2017 will be a pivotal year. Utilizing purpose-built proprietary 3D printing market models, the report is able to present detailed market forecast data on thermoplastic filaments, powders, photopolymers, composites, and more utilized in popular print technologies of material extrusion (FDM, FFF), polymer powder bed fusion (SLS, Multi Jet Fusion), photopolymerization (SLA, DLP, CLIP), binder jetting, and more. All available materials for primary polymer print technologies are analyzed and forecasted, including market revenues as well as material shipments, by industry and geography, over the next decade. Therefore, the report believes that Opportunities in Polymer and Plastic 3D Printing - 2017 will provide exceptional value to business development professionals and internal market strategy teams for the global chemical and polymer industries, as well as polymer 3D printer manufacturers, print service providers, and developers of polymer 3D printing manufacturing solutions. Key Topics Covered: Chapter One: Review of Current Market Trends and Dynamics in Polymer 3D Printing 1.1 Segmenting the Polymer 3D Printing Market: Specialized Processes versus Manufacturing Processes 1.1.1 Material Extrusion - A Flexible and Cost Effective Process for Low- to Medium- Volume Manufacturing 1.1.2 Polymer Powder Bed Fusion - A Highly Scalable Process for Volume Manufacturing and High-Performance Parts 1.1.3 Photopolymerization - A Multifunctional Process for Mass Customization 1.1.4 Material Jetting - A Specialized Process for High-Value Multifunctional Output 1.1.5 Binder Jetting - A Specialized Process for High Volume, Large Models 1.2 Polymer 3D Printing Market in Period of Transition Through 2017 1.2.1 Ongoing Influence of Low-Cost 3D Printers in the Polymer Printing Segment 1.3 Analysis of Growth Drivers and Emerging Dynamics in Polymer Additive Manufacturing and 3D Printing 1.3.1 Markets Demand Greater Strides in Open Architecture for Professional and Industrial Polymer 3D Printers 1.3.2 Global Polymer and Chemical Providers Will Take Center Stage in Polymer 3D Printing by 2019 1.3.3 Current Go-to-Market Strategies for Polymer Print Material Developers 1.3.3.1 Development of Branded Third-Party Product Lines for Direct Sales to End Users 1.3.3.2 Sale of Feedstock or Private Label Materials to 3D OEMs or Third-Party Material Compounders and Developers 1.3.4 Market Growth Scenarios, 2017 through 2019 1.4 Major Adopters of Polymer 3D Printing Technology by Industry - Trends and Future Growth Drivers 1.4.1 Polymer 3D Printing in the Automotive Industry - Leading in Potential for Volume Manufacturing and Prototyping 1.4.2 Medical 3D Printing a Short-Term Driver for Current Polymer Printing 1.4.3 3D Printing Increasingly Disruptive in Dentistry as a Digital Production Tool 1.4.4 Aerospace Industry Rallying Around Polymer 3D Printing for Strategic Manufacturing Solution in Aircraft Interiors 1.4.5 Balancing Expectations for Polymer 3D Printing in the Jewelry Industry Versus Direct Metal AM Production 1.5 2016 Market in Review - Setting the Stage for a Global Manufacturing Revolution? 1.5.1 Major Hardware Market Competitive Shakeup - Hewlett Packard, Carbon, Farsoon, and Prodways 1.5.2 Global Polymer and Chemical Companies Make Significant Commitments to 3D Printing in 2016/2017 1.5.3 Cincinnati Inc., Stratasys, Others Look to Revolutionize the Value Propositions of Existing Processes Through New Vision 1.6 Summary of Ten-Year Forecasts for Polymer 3D Printing Materials Chapter Two: Opportunities for Polymer 3D Printing Hardware and Materials in Material Extrusion Technology 2.1 Global Material Extrusion Market Metrics and Landscape 2.2 Characterizing the Material Extrusion Process 2.3 Influential Applications and Major Markets for Material Extrusion 3D Printing 2.4 Opportunities in Print Materials and Polymers in Material Extrusion 2.4.1 Established Thermoplastics for Material Extrusion 2.4.1.1 Nylon/Polyamide 2.4.1.2 ABS 2.4.1.3 Other Amorphous Thermoplastics - Polycarbonate, ASA, and TPU 2.4.2 Emerging Thermoplastic Material Opportunities in Material Extrusion 2.4.2.1 Opportunities in Amorphous Thermoplastics - PVC and PEI 2.4.2.2 Opportunities in Semicrystalline Thermoplastics - PAEK Polymers, Polyethylene, and Polypropylene 2.4.2.3 Thermoplastic Composites Utilizing Material Extrusion 2.5 Major Players and Influencers in the Material Extrusion Segment - Materials and Hardware 2.5.1 Stratasys 2.5.2 TierTime 2.5.3 Arburg 2.5.3 Bolson Materials/Argyle Materials 2.5.4 taulman3D 2.5.5 SABIC 2.5.6 Cincinnati Incorporated Chapter Three: Opportunities for Polymer 3D Printing Hardware and Materials in Powder Bed Fusion Technology 3.1 Global Powder Bed Fusion Market Metrics and Landscape 3.2 Characterizing Polymer Powder Bed Fusion Technology 3.3 Influential Applications and Major Markets for Powder Bed Fusion 3D Printing 3.4 Opportunities in Print Materials and Polymers in Powder Bed Fusion 3.4.1 Established Powder Bed Fusion Thermoplastics and Polymers 3.4.1.1 Neat Polyamides and Composite Polyamide Materials (Nylons) 3.4.1.2 PEEK and PEKK 3.4.1.3 Polystyrene 3.4.2 Emerging Opportunities in Thermoplastics and Polymers for Powder Bed Fusion 3.4.2.1 TPU and Elastomeric Polymers 3.4.2.2 Semicrystalline Polymers - Polypropylene and Polyethylene, and High-Performance Semicrystalline Thermoplastics 3.4.2.3 Ceramics and Sand Processing Using Polymer Powder Bed Fusion Systems 3.5 Major Players and Influencers in the Powder Bed Fusion Segment - Materials and Hardware 3.5.1 3D Systems 3.5.2 EOS 3.5.3 Evonik 3.5.4 Arkema 3.5.5 Prodways and Farsoon (including ExcelTec) 3.5.6 Solvay 3.5.7 Oxford Performance Materials 3.5.8 CRP Technologies 3.5.9 BASF 3.5.10 Lehmann & Voss 3.5.11 Xaar/voxeljet Chapter Four: Opportunities for Polymer 3D Printing Hardware and Materials in Photopolymerization and Material Jetting Technologies 4.1 Global Photopolymer 3D Printing Market Metrics and Landscape 4.1.1 Photopolymerization 4.1.2 Material Jetting 4.2 Photopolymerization Methods versus Material Jetting 4.3 Influential Applications and Major Markets for Photopolymer-Based 3D Printing 4.4 Opportunities in Print Materials and Polymers for Photopolymer Printing 4.4.1 Current Photopolymer Materials for Printing in Photopolymerization and Material Jetting Technologies 4.4.2 Development of Specialized Photopolymerization and Jetting Print Technologies for Printing in Established Polymer Materials 4.4.3 Development of Resins for Manufacturing Applications in End-Use Parts 4.5 Major Players and Influencers in the Photopolymer 3D Printing Segment - Materials and Hardware 4.5.1 3D Systems 4.5.2 EnvisionTEC 4.5.3 DSM Somos (Royal DSM) 4.5.4 Sartomer (Arkema) 4.5.5 DeltaMed and Prodways 4.5.6 Henkel 4.5.7 Carbon Chapter Five: Opportunities for Polymer 3D Printing Hardware and Materials in Other and Emerging Print Technologies 5.1 Binder Jetting with Polymers - Is Polymer Binder Jetting Viable for the Future? 5.1.1 Process Characteristics and Marketplace for Polymer Binder Jetting Technology 5.1.2 Available and Future Materials for Polymer Binder Jetting 5.1.3 Notable Players for Polymer Binder Jetting and Future Outlook 5.1.3.1 Future Outlook for Binder Jetting 5.2 Lamination Based Processes - New Life in 2017 through Composite Processing 5.2.1 EnvisionTEC SLCOM1 Thermoplastic Composite 3D Printer 5.2.2 Future of Lamination-Based 3D Printing Processes 5.3 Specialized and Emerging Polymer 3D Printing Processes - Bringing Further Potential Disruption 5.3.1 Creating Enhanced 3D Printing Processes Through Hybridization Chapter Six: Ten-Year Market Forecasts for Polymer and Plastic 3D Printing 6.1 Methodologies and Assumptions 6.2 Presentation of Key Market Metrics 6.3 Material Extrusion Market Data 6.4 Polymer Powder Bed Fusion Market Data 6.5 Photopolymer 3D Printing Technology Market Data 6.6 Binder Jetting Market Data 6.7 Industry Market Data For more information about this report visit http://www.researchandmarkets.com/research/rkgv69/opportunities_in Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-polymer-and-plastic-3d-printing-opportunity-analysis-and-ten-year-forecasts-2017-2027---research-and-markets-300464103.html


HEERLEN, Netherlands and EMERYVILLE, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS), the global science-based company active in health, nutrition and materials, today announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).  Amyris’ technology supports DSM’s strategic markets in health, nutrition, and materials as well as a growing consumer shift to (bio-) natural-like products derived from sustainable sources. For Amyris, DSM’s channels and market access and keen understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value. Equity Investment DSM has agreed to make an initial equity investment in Amyris of US$25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris. The first tranche is expected to close on Thursday, 11 May 2017, with a second tranche, if approved by DSM’s Managing Board, expected to close within 90 days of the closing of the first tranche. As part of this investment, DSM will gain one board seat upon the closing of each tranche. As part of the agreement, DSM and Amyris have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients. “We are very excited about DSM’s strategic focus in health and nutrition markets and its commitment to sustainable sourcing and production of better-performing products,” said John Melo, Amyris President & CEO. “The Amyris technology platform and potential synergy can lead to significant cost improvements for DSM while accelerating Amyris’s market access. We expect this will lead to incremental revenue in 2017, growing annually based on the number of products we develop in our partnership and our pace of delivery.” “Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, President & CEO of DSM Nutritional Products. “Working closely together with Amyris and leveraging DSM’s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products." Terms of the private placement and related agreements are more fully disclosed in the Form 8-K filed by Amyris today with the Securities and Exchange Commission, available free of charge at sec.gov. DSM – Bright Science. Brighter Living.™  Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. DSM Forward-Looking Statements This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading. Amyris Forward-Looking Statements This release contains forward-looking statements regarding Amyris, and any statements regarding Amyris other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the anticipated establishment of a long-term relationship between Amyris and DSM, including the expected entry into a development cooperation focused on products for the global health and nutrition markets, the anticipated closing of the first tranche of the financing referenced above, including the timing thereof, the expected closing of a second tranche of financing, including the timing thereof, and anticipated acceleration of Amyris’s market access, and expected revenue and revenue growth in 2017 and beyond, resulting from the partnership with DSM) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


HEERLEN, Netherlands and EMERYVILLE, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, and Koninklijke DSM N.V. (Royal DSM) (AEX:DSM.AS), the global science-based company active in health, nutrition and materials, today announced that they have agreed for DSM to make an equity investment in Amyris. At the same time, the companies will enter into a development cooperation focused on products for the global health and nutrition markets (including vitamins and other nutritional ingredients).  Amyris’ technology supports DSM’s strategic markets in health, nutrition, and materials as well as a growing consumer shift to (bio-) natural-like products derived from sustainable sources. For Amyris, DSM’s channels and market access and keen understanding in selecting the right products for the animal nutrition, human nutrition, and consumer health markets provide strategic value. Equity Investment DSM has agreed to make an initial equity investment in Amyris of US$25 million, translating into a shareholding of ~12%. Subject to the satisfaction of certain conditions, DSM may invest an additional US$25 million in Amyris. The first tranche is expected to close on Thursday, 11 May 2017, with a second tranche, if approved by DSM’s Managing Board, expected to close within 90 days of the closing of the first tranche. As part of this investment, DSM will gain one board seat upon the closing of each tranche. As part of the agreement, DSM and Amyris have agreed to focus on a number of short- to medium-term product development & production opportunities in vitamins and other nutritional ingredients. “We are very excited about DSM’s strategic focus in health and nutrition markets and its commitment to sustainable sourcing and production of better-performing products,” said John Melo, Amyris President & CEO. “The Amyris technology platform and potential synergy can lead to significant cost improvements for DSM while accelerating Amyris’s market access. We expect this will lead to incremental revenue in 2017, growing annually based on the number of products we develop in our partnership and our pace of delivery.” “Amyris has a unique yeast-based strain engineering platform that is very complementary to DSM’s capabilities in this area and will create great synergy with DSM’s know-how in fermentation, downstream process development and large-scale manufacturing,” said Chris Goppelsroeder, President & CEO of DSM Nutritional Products. “Working closely together with Amyris and leveraging DSM’s route-to-market, will accelerate our innovation towards cost-effective, fermentation-based processes for both existing and new products." Terms of the private placement and related agreements are more fully disclosed in the Form 8-K filed by Amyris today with the Securities and Exchange Commission, available free of charge at sec.gov. DSM – Bright Science. Brighter Living.™  Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at www.dsm.com. About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com. DSM Forward-Looking Statements This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading. Amyris Forward-Looking Statements This release contains forward-looking statements regarding Amyris, and any statements regarding Amyris other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the anticipated establishment of a long-term relationship between Amyris and DSM, including the expected entry into a development cooperation focused on products for the global health and nutrition markets, the anticipated closing of the first tranche of the financing referenced above, including the timing thereof, the expected closing of a second tranche of financing, including the timing thereof, and anticipated acceleration of Amyris’s market access, and expected revenue and revenue growth in 2017 and beyond, resulting from the partnership with DSM) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other risks detailed in the “Risk Factors” section of Amyris’s annual report on Form 10-K filed on April 17, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise. Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.


News Article | May 4, 2017
Site: startupjuncture.com

The Ocean Cleanup, a foundation with the aim to get rid of plastics in the world’s oceans just got support from a number prominent investors and philanthropists. In a round led by the Marc and Lynne Benioff foundation, of Salesforce founder and billionaire Marc Benioff, and an anonymous donor, the foundation raised 21.7 million USD in donations. Other supporters include the Julius Baer Foundation, Royal DSM, and Peter Thiel. The new round brings the total funding of The Ocean Cleanup since 2013 to 31.5 million USD. Founded by Boyan Slat in 2012, while he was still a student at Delft University of Technology, The Ocean Cleanup is developing advanced technologies to rid of the oceans of plastic. By creating artificial coastlines on sea and using the ocean’s current to collect the plastic the foundation can get rid of ‘plastic soup’ in a fraction of the time and cost of more conventional methods. To accelerate the process even more Slat aims to create artificial coastlines as long as 100 kilometres. The collected plastic will subsequently be transported by ships to shore where it can be recycled. The new donation allows the foundation to initiate large-scale trials of this technology in the Pacific Ocean later this year. “Lynne and I are thrilled to support The Ocean Cleanup’s important goal of eliminating plastic in our oceans,” said Benioff in a press release about the announcement. Benioff: ”With Boyan’s innovative leadership, I believe The Ocean Cleanup will have an incredibly positive impact on the future of our oceans. I hope other leaders will join us in supporting these efforts.” “Our mission is to rid the world’s oceans of plastic, and this support is a major leap forward towards achieving this goal. Thanks to the generous support of these funders, the day we’ll be returning that first batch of plastic to shore is now in sight”, says Slat about the new support for his foundation. Details on this project and the start of the cleanup will be shared with 3000 of the supporters of the foundation at an event on Thursday May 11th at the Werkspoorkathedraal in Utrecht, the Netherlands and followed by a media Q&A session. You can register for the event here.


Wiseguyreports.Com Adds “Functional Food Ingredients -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database Geographically, this report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Functional Food Ingredients in these regions, from 2012 to 2022 (forecast), covering USA China Europe Japan India Southeast Asia On the basis of product, the Functional Food Ingredients market is primarily split into On the basis on the end users/applications, this report covers Natural pigment Sweetening substitute Thickener Emulsifier Preservative Global Functional Food Ingredients Sales Market Report 2017 1 Functional Food Ingredients Market Overview 1.1 Product Overview and Scope of Functional Food Ingredients 1.2 Classification of Functional Food Ingredients by Product Category 1.2.1 Global Functional Food Ingredients Sales (Metric Tons) and Growth (%) Comparison by Types (2012-2022) 1.2.2 Global Functional Food Ingredients Sales Market Share (%) by Types in 2016 1.2.3 Protein 1.2.4 Vitamin 1.2.5 Mineral 1.3 Global Functional Food Ingredients Market by Applications/End Users 1.3.1 Global Functional Food Ingredients Sales (Metric Tons) Comparison by Applications (2012-2022) 1.3.2 Natural pigment 1.3.3 Sweetening substitute 1.3.4 Thickener 1.3.5 Emulsifier 1.3.6 Preservative 1.4 Global Functional Food Ingredients Market by Regions 1.4.1 Global Functional Food Ingredients Revenue (Million USD) Comparison by Regions (2012-2022) 1.4.2 United States Functional Food Ingredients Status and Prospect (2012-2022) 1.4.3 China Functional Food Ingredients Status and Prospect (2012-2022) 1.4.4 Europe Functional Food Ingredients Status and Prospect (2012-2022) 1.4.5 Japan Functional Food Ingredients Status and Prospect (2012-2022) 1.4.6 Southeast Asia Functional Food Ingredients Status and Prospect (2012-2022) 1.4.7 India Functional Food Ingredients Status and Prospect (2012-2022) 1.5 Global Functional Food Ingredients Sales and Revenue (2012-2022) 1.5.1 Global Functional Food Ingredients Sales (Metric Tons) and Growth Rate (%) (2012-2022) 1.5.2 Global Functional Food Ingredients Revenue (Million USD) and Growth Rate (2012-2022) 9 Global Functional Food Ingredients Players Profiles and Sales Data 9.1 DuPont 9.1.1 Company Basic Information, Manufacturing Base and Competitors 9.1.2 Functional Food Ingredients Product Category, Application and Specification 9.1.2.1 Product A 9.1.2.2 Product B 9.1.3 DuPont Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.1.4 Main Business/Business Overview 9.2 Archer Daniels Midland (ADM) 9.2.1 Company Basic Information, Manufacturing Base and Competitors 9.2.2 Functional Food Ingredients Product Category, Application and Specification 9.2.2.1 Product A 9.2.2.2 Product B 9.2.3 Archer Daniels Midland (ADM) Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.2.4 Main Business/Business Overview 9.3 Kerry Group 9.3.1 Company Basic Information, Manufacturing Base and Competitors 9.3.2 Functional Food Ingredients Product Category, Application and Specification 9.3.2.1 Product A 9.3.2.2 Product B 9.3.3 Kerry Group Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.3.4 Main Business/Business Overview 9.4 Associated British Foods 9.4.1 Company Basic Information, Manufacturing Base and Competitors 9.4.2 Functional Food Ingredients Product Category, Application and Specification 9.4.2.1 Product A 9.4.2.2 Product B 9.4.3 Associated British Foods Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.4.4 Main Business/Business Overview 9.5 BASF 9.5.1 Company Basic Information, Manufacturing Base and Competitors 9.5.2 Functional Food Ingredients Product Category, Application and Specification 9.5.2.1 Product A 9.5.2.2 Product B 9.5.3 BASF Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.5.4 Main Business/Business Overview 9.6 Ingredion 9.6.1 Company Basic Information, Manufacturing Base and Competitors 9.6.2 Functional Food Ingredients Product Category, Application and Specification 9.6.2.1 Product A 9.6.2.2 Product B 9.6.3 Ingredion Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.6.4 Main Business/Business Overview 9.7 Tate & Lyle 9.7.1 Company Basic Information, Manufacturing Base and Competitors 9.7.2 Functional Food Ingredients Product Category, Application and Specification 9.7.2.1 Product A 9.7.2.2 Product B 9.7.3 Tate & Lyle Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.7.4 Main Business/Business Overview 9.8 Arla Foods 9.8.1 Company Basic Information, Manufacturing Base and Competitors 9.8.2 Functional Food Ingredients Product Category, Application and Specification 9.8.2.1 Product A 9.8.2.2 Product B 9.8.3 Arla Foods Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.8.4 Main Business/Business Overview 9.9 Cargill 9.9.1 Company Basic Information, Manufacturing Base and Competitors 9.9.2 Functional Food Ingredients Product Category, Application and Specification 9.9.2.1 Product A 9.9.2.2 Product B 9.9.3 Cargill Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.9.4 Main Business/Business Overview 9.10 Royal DSM 9.10.1 Company Basic Information, Manufacturing Base and Competitors 9.10.2 Functional Food Ingredients Product Category, Application and Specification 9.10.2.1 Product A 9.10.2.2 Product B 9.10.3 Royal DSM Functional Food Ingredients Sales (Metric Tons), Revenue (Million USD), Price (USD/Metric Tons) and Gross Margin (%) (2012-2017) 9.10.4 Main Business/Business Overview 9.11 American International Chemical For more information, please visit https://www.wiseguyreports.com/sample-request/1193285-global-functional-food-ingredients-sales-market-report-2017


Ager D.J.,DSM Innovative Synthesis BV | De Vries A.H.M.,Royal DSM | De Vries J.G.,Royal DSM
Chemical Society Reviews | Year: 2012

Asymmetric hydrogenations are increasingly being used to introduce stereogenic centres into products used in the life sciences industries. There are a number of potential pitfalls when moving from a laboratory reaction to a manufacturing process, not least of which is safety. Time-to-market pressure leads to short development times, which in the past could be a large barrier for the implementation of catalytic steps; now there are new ways to minimise this problem. The potential problems associated with impurities and other methods that can shut down the hydrogenation reactions are highlighted in this critical review (353 references). © 2012 The Royal Society of Chemistry.


De Vries J.G.,Royal DSM
Topics in Organometallic Chemistry | Year: 2012

Palladium-catalysed coupling reactions have gained importance as a tool for the production of pharmaceutical intermediates and to a lesser extent also for the production of agrochemicals, flavours and fragrances, and monomers for polymers. In this review only these cases are discussed where it seems highly likely that the technology is or has been used for ton-scale production. We document twelve cases where the Mizoroki-Heck reaction was used to arylate an alkene. In two of these cases allylic alcohols were arylated, leading to the aldehyde or the ketone. The Suzuki reaction has been used mostly to produce biaryl compounds from aryl halides and arylboronic acid derivatives. Twelve processes were recorded. Ortho-tolyl-benzonitrile, a biaryl compound produced via the Suzuki reaction, is used as an intermediate in six different pharmaceuticals all belonging to the Sartan group of blood pressure-lowering agents. The Kumada-Corriu reaction in which an aryl or alkenyl Grignard is coupled to an aryl or alkenyl halide was used nine times. In these coupling reactions palladium is often replaced by the much cheaper nickel or iron catalysts. The Negishi reaction couples an arylzinc halide with an aryl or alkenyl halide. These reactions are fast and highly selective; the only drawback being the stoichiometric zinc waste. Two cases were found. In one of these it was possible to use only a catalytic amount of zinc (double metal catalysis). The Sonogashira reaction couples a terminal alkyne to an aryl or alkenyl halide. Three cases were found. Acetylene is usually not coupled as such in view of its instability. Instead, trimethylsilylacetylene or the acetylene acetone adduct is used. Finally, one case was found of a palladium-catalysed allylic substitution and one case of a CH-activation reaction to form a benzocyclobutane ring. Most of these reactions were implemented in production in the past ten years. © 2012 Springer-Verlag Berlin Heidelberg.


Sagt C.M.J.,Royal DSM
Applied Microbiology and Biotechnology | Year: 2013

Systems metabolic engineering is based on systems biology, synthetic biology, and evolutionary engineering and is now also applied in industry. Industrial use of systems metabolic engineering focuses on strain and process optimization. Since ambitious yields, titers, productivities, and low costs are key in an industrial setting, the use of effective and robust methods in systems metabolic engineering is becoming very important. Major improvements in the field of proteomics and metabolomics have been crucial in the development of genome-wide approaches in strain and process development. This is accompanied by a rapid increase in DNA sequencing and synthesis capacity. These developments enable the use of systems metabolic engineering in an industrial setting. Industrial systems metabolic engineering can be defined as the combined use of genome-wide genomics, transcriptomics, proteomics, and metabolomics to modify strains or processes. This approach has become very common since the technology for generating large data sets of all levels of the cellular processes has developed quite fast into robust, reliable, and affordable methods. The main challenge and scope of this mini review is how to translate these large data sets in relevant biological leads which can be tested for strain or process improvements. Experimental setup, heterogeneity of the culture, and sample pretreatment are important issues which are easily underrated. In addition, the process of structuring, filtering, and visualization of data is important, but also, the availability of a genetic toolbox and equipment for medium/high-throughput fermentation is a key success factor. For an efficient bioprocess, all the different components in this process have to work together. Therefore, mutual tuning of these components is an important strategy. © 2013 Springer-Verlag Berlin Heidelberg.

Loading Royal DSM collaborators
Loading Royal DSM collaborators